32,439 results match your criteria Lymphoma Diffuse Large Cell


Tisagenlecleucel in Diffuse Large B-Cell Lymphoma. Reply.

N Engl J Med 2019 Apr;380(16):1586

University of Pennsylvania, Philadelphia, PA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1901464DOI Listing

Tisagenlecleucel in Diffuse Large B-Cell Lymphoma.

N Engl J Med 2019 Apr;380(16):1585-1586

Rocket Pharmaceuticals, New York, NY

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1901464DOI Listing

Tisagenlecleucel in Diffuse Large B-Cell Lymphoma.

N Engl J Med 2019 Apr;380(16):1585

McGill University, Montreal, QC, Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1901464DOI Listing

Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.

Clin Lymphoma Myeloma Leuk 2019 Mar 11. Epub 2019 Mar 11.

Division of Hematology/Oncology, University of Virginia, Charlottesville, VA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.03.001DOI Listing

Designing optimal prognostic models for diffuse large B-cell lymphoma.

Leuk Lymphoma 2019 Apr 16:1-3. Epub 2019 Apr 16.

c Department of Hematology , Sir Charles Gairdner Hospital , Nedlands , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1599117DOI Listing

X-Linked Lymphoproliferative Syndrome Presenting as Adult-Onset Multi-Infarct Dementia.

J Neuropathol Exp Neurol 2019 May;78(5):460-466

Department of Neurology, Mayo Clinic, Jacksonville, Florida.

Pathogenic hemizygous variants in the SH2D1A gene cause X-linked lymphoproliferative (XLP) syndrome, a rare primary immunodeficiency usually associated with fatal Epstein-Barr virus infection. Disease onset is typically in early childhood, and the average life expectancy of affected males is ∼11 years. We describe clinical, radiographic, neuropathologic, and genetic features of a 49-year-old man presenting with central nervous system vasculitis that was reminiscent of adult primary angiitis but which was unresponsive to treatment. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jnen/article/78/5/460/5445919
Publisher Site
http://dx.doi.org/10.1093/jnen/nlz018DOI Listing
May 2019
1 Read

Rare presentation of disseminated follicular lymphoma as an ill-defined reticular patch over the scalp and forehead.

JAAD Case Rep 2019 Apr 2;5(4):319-322. Epub 2019 Apr 2.

Department of Dermatology, Harbor UCLA Medical Center, Torrance, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2019.02.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447722PMC

The expression level of hsa-miR-146a-5p in plasma-derived exosomes of patients with diffuse large B-cell lymphoma.

J Res Med Sci 2019 25;24:10. Epub 2019 Feb 25.

Department of Physiology, School of Medicine and Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Background: The standard treatment for patients with diffuse large B-cell lymphoma (DLBCL) had been rituximab-based immunochemotherapy. However, the biological and clinical heterogeneity within DLBCL seems to affect treatment outcome. Therefore, the evaluation of miRNA levels might be useful in predicting treatment response and relapse risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jrms.JRMS_507_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421886PMC
February 2019

Leg Type Primary Cutaneous Diffuse Large B-Cell Lymphoma.

Indian J Hematol Blood Transfus 2019 Apr 29;35(2):378-379. Epub 2018 Oct 29.

Pathology Unit, IRCCS Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-018-1036-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439055PMC

Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma.

Cell Death Dis 2019 Apr 15;10(5):330. Epub 2019 Apr 15.

Department of Radiotherapy, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

High mobility group box 1 (HMGB1) protein in the tumor microenvironment actively contributes to tumor progression but its role in diffuse large B-cell lymphoma (DLBCL) is unknown. The aim of this study was to determine the mechanism by which HMGB1 promotes tumor growth in DLBCL and whether blockade of HMGB1 signaling pathway could inhibit tumorigenesis. We report that HMGB1 promotes proliferation of DLBCL cells by activation of AKT, extracellular signal-regulated kinases 1/2 (ERK1/2), signal transducer and activator of transcription 3 (STAT3) and SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase (Src). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-019-1563-8DOI Listing

Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders.

Kidney Int 2019 Mar 15. Epub 2019 Mar 15.

Department of Nephrology and Renal Transplantation, Centre Hospitalier Universitaire, Université de Poitiers, Poitiers, France; CNRS UMR 7276, INSERM UMR 1262, Université de Limoges, Limoges, France; INSERM CIC 1402, Centre Hospitalier Universitaire, Poitiers, France.

The clinicopathological characteristics of kidney infiltration in B-cell lymphoproliferative disorders remain poorly described. We retrospectively studied 52 adults with biopsy-proven malignant B-cell kidney infiltration, including Waldenström's macroglobulinemia (n=21), chronic lymphocytic leukemia (n=11), diffuse large B-cell lymphoma (DLBCL) (n=8), other lymphoma (n=11), and multiple myeloma (n=1). Kidney disease varied according to the underlying lymphoproliferative disorder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.kint.2019.01.027DOI Listing

Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway.

Cancer Epidemiol 2019 Apr 12;60:128-133. Epub 2019 Apr 12.

Department of Haematology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; K.G. Jebsen Centre for B-Cell malignancies, University of Oslo, Oslo, Norway.

Background: Transformation to aggressive lymphoma (Richter syndrome, RS) occurs in a substantial subset of patients who must discontinue targeted therapy for chronic lymphocytic leukemia (CLL). RS has an extremely poor prognosis.

Methods: Using the nation-wide database of The Cancer Registry of Norway of 7664 CLL patients registered between 1953-2012, we identified 107 patients experiencing RS. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18777821183046
Publisher Site
http://dx.doi.org/10.1016/j.canep.2019.04.002DOI Listing
April 2019
1 Read

CD20-negative primary middle ear diffuse large B-cell lymphoma coexpressing MYC and BCL-2 secondary to acute lymphoblastic leukemia: A case report.

Medicine (Baltimore) 2019 Apr;98(15):e15204

Department of Hematology, The First Affiliated Hospital, Kunming Medical University, Kunming, Yunnan Province, China.

Rationale: Second diffuse large B-cell lymphoma (DLBCL) after treatment of acute lymphoblastic leukemia (ALL) is uncommon. To our knowledge, primary middle ear DLBCL which presents CD20-negative and coexpression of MYC and BCL-2 has not been reported yet.

Patient Concerns: A 20-year-old Chinese man complained fever and weakness for 2 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000015204DOI Listing

Diffuse large B-cell lymphoma involving peripheral nervous system with IgM antibodies against GM1 and GD1b: A case report.

Medicine (Baltimore) 2019 Apr;98(15):e15049

Department of Neurology and Neuroscience Center, First Hospital of Jilin University, Changchun, Jilin, China.

Rationale: The occurrence of peripheral neuropathy associated with non-Hodgkin's lymphoma (NHL) is uncommon. And autoimmunity may play an important role. We report a case of the patient with NHL, has sensorimotor demyelinating polyneuropathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000015049DOI Listing
April 2019
1 Read

Investigation of lymphoid lesions of the Head and Neck using combined fine needle aspiration cytology and flow cytometry: accuracy and pitfalls.

Cytopathology 2019 Apr 15. Epub 2019 Apr 15.

Cytology Department, Sullivan Nicolaides Pathology, 24 Hurworth St, Bowen Hills, 4006.

Objective: We reviewed the diagnostic utility of combined fine needle aspiration cytology (FNAC) and flow cytometry (FC) in the diagnosis of lymphoid lesions of the head and neck.

Method: 1402 patients with combined FNAC-FC reports were correlated with follow-up information. Rapid on-site evaluation (ROSE) of cytological specimens was performed in 52% of cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cyt.12706DOI Listing

A case of pulmonary lymphoproliferative disorder presenting rapidly progressive respiratory failure.

Respirol Case Rep 2019 Jul 2;7(5):e00422. Epub 2019 Apr 2.

Division of Respiratory Medicine, Center for Respiratory Diseases National Hospital Organization Kyoto Medical Center Kyoto Japan.

A 72-year-old woman presented with acute onset of shortness of breath and fatigue over several days, and was found to be in acute respiratory failure. Computed tomography of the chest revealed diffuse ground-glass opacities, crazy-paving, multiple nodules, and a large mass in the right lower lobe. She was diagnosed with B-cell lymphoma and a pulmonary lymphoproliferative disorder (PLD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/rcr2.422DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444548PMC

Non-Hodgkin Lymphoma in the Middle East Is Characterized by Low Incidence Rates With Advancing Age.

J Glob Oncol 2019 Apr(5):1-10

3 Shorsh General and Hiwa Cancer Hospitals, Sulaimaniyah, Iraq.

Purpose: In the Middle East, incidence rate ratios (IRRs) of non-Hodgkin lymphoma (NHL) to Hodgkin lymphoma (HL) are more than 50% lower than the United States.

Materials And Methods: Age-specific incidence rates (ASIRs), age-adjusted incidence rates (AAIRs), and IRRs of NHL:HL were compared using the cancer registries of Iraq, Jordan, Saudi Arabia, and US SEER.

Results: The NHL AAIR (95% CI) per 100,000 population was 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.18.00241DOI Listing
April 2019
1 Read

Fibrin-associated diffuse large B-cell lymphoma arising in a mature cystic teratoma: A case report.

Pathol Int 2019 Apr 12. Epub 2019 Apr 12.

Department of Gastroenterology, Chikamori Hospital, Kochi, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pin.12788DOI Listing
April 2019
1 Read

Seroepidemiological analysis and literature review of the prevalence of Epstein-Barr virus and herpesvirus infections in pediatric cases with non-Hodgkin lymphoma in Central Europe.

Pediatr Blood Cancer 2019 Apr 12:e27752. Epub 2019 Apr 12.

Department of Pediatric Hematology and Oncology, Justus Liebig University Giessen, Giessen, Germany.

Background: Epstein-Barr virus (EBV) is linked to a variety of malignancies; most endemic Burkitt lymphoma (BL) harbor EBV, whereas only a subset of the cases of sporadic BL is EBV positive.

Procedure: We retrospectively determined the herpesvirus seroprevalence at the time of diagnosis in pediatric non-Hodgkin lymphoma (NHL) patients enrolled in NHL-BFM (Berlin-Frankfurt-Muenster) studies. We accessed the seroepidemiological data from 1147 patients that became available during 1990-2007. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27752DOI Listing
April 2019
1 Read

PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B cell diffuse large B-cell lymphomas.

Blood 2019 Apr 11. Epub 2019 Apr 11.

Hemato-Oncology, Center for Applied Medical Research (CIMA) University of Navarra, Spain

Refractory or relapsed diffuse large B-cell lymphoma (DLBCL) often associates with the activated B cell-like (ABC) subtype and genetic alterations that drive constitutive NF-kB activation and impair B cell terminal differentiation. Here, we show that DNA damage response by p53 is a central mechanism suppressing the pathogenic cooperation of IKK2ca-enforced canonical NF-kB and impaired differentiation due to Blimp1 loss in ABC-DLBCL lymphomagenesis. We provide evidences that the interplay between these genetic alterations and the tumor microenvironment (TME) select for additional molecular addictions that promote lymphoma progression, including aberrant co-expression of FOXP1 and the B-cell mutagenic enzyme AID, and immune evasion through MHC-II downregulation, PD-L1 upregulation and T-cell exhaustion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2018889931DOI Listing
April 2019
1 Read
10.452 Impact Factor

The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients.

Int J Cancer 2019 Apr 11. Epub 2019 Apr 11.

Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea.

Erythropoiesis-stimulating agents (ESAs), such as erythropoietin (EPO) and darbepoetin, may alleviate anemia in diffuse large B-cell lymphoma (DLBCL) patients. However, many cancer cells express EPO receptors (EPOR), through which exogenously-administered ESAs potentially promote cancer cell growth. We conducted preclinical/phase II studies to investigate the safety and efficacy of ESAs for managing chemotherapy-related anemia in DLBCL patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32328DOI Listing
April 2019
1 Read

Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification.

Eur J Haematol 2019 Apr 10. Epub 2019 Apr 10.

Department of Hematology, Hospital del Mar, Barcelona, Spain.

Objective: To evaluate the role of N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and a cardiovascular (CV) risk score named FRESCO for predicting anthracycline-induced cardiotoxicity (AIC) in diffuse large B-cell lymphoma (DLBCL).

Methods: 130 consecutive DLBCL patients treated in first-line with anthracycline-containing immunochemotherapy. Competitive risk between NT-proBNP, FRESCO and time to AIC was considered. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13234
Publisher Site
http://dx.doi.org/10.1111/ejh.13234DOI Listing
April 2019
2 Reads

Non-Hodgkin's lymphoma with extensive emperipolesis mimicking Rosai-Dorfman disease: A rare case report.

Indian J Pathol Microbiol 2019 Apr-Jun;62(2):319-322

Department of Pathology, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospital, Pune, Maharashtra, India.

Emperipolesis is the hallmark finding for Rosai-Dorfman disease. Till now many studies in literatures have shown emperipolesis as a finding in other benign as well as malignant conditions. Very few cases of malignant lymphoma have this phenomenon. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/IJPM.IJPM_409_18DOI Listing
April 2019
1 Read

Physical torment: A predisposition for diffuse B-cell lymphoma.

J Oral Maxillofac Pathol 2019 Feb;23(Suppl 1):17-22

Department of Oral and Maxillofacial Surgery, GSL Dental College, Rajahmundry, Andhra Pradesh, India.

Lymphomas of the oral cavity are rare and represent only 3%-5% of all lymphomas. Diffuse large B-cell lymphomas (DLBCLs) are a heterogeneous group of tumor and the most common type of all non-Hodgkin's lymphomas (NHLs). They mostly arise from soft tissue as asymptomatic swelling and involvement of jaw bones is infrequent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jomfp.JOMFP_7_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421932PMC
February 2019
1 Read

Evaluation of a case of diffuse large B-cell lymphoma.

J Oral Maxillofac Pathol 2019 Feb;23(Suppl 1):7-11

Department of Oral and Maxillofacial Pathology and Microbiology, Sri Guru Ram Das Institute of Dental Sciences and Research, Amritsar, Punjab, India.

Lymphomas are a group of malignant blood cell tumors that develop from lymphocytes representing 2.2% of all malignant neoplasms of the head and neck. Two main categories of lymphomas are Hodgkin's lymphoma and non-Hodgkin's lymphoma (NHL) of which 90% are of the NHL type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jomfp.JOMFP_100_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421931PMC
February 2019
4 Reads

MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.

Blood Adv 2019 Apr;3(7):1185-1196

Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.

A major clinical challenge of diffuse large B-cell lymphoma (DLBCL) is that up to 40% of patients have refractory disease or relapse after initial response to therapy as a result of drug-specific molecular resistance. The purpose of the present study was to investigate microRNA (miRNA) involvement in vincristine resistance in DLBCL, which was pursued by functional in vitro analysis in DLBCL cell lines and by outcome analysis of patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Differential miRNA expression analysis identified miR-155 as highly expressed in vincristine-sensitive DLBCL cell lines compared with resistant ones. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018029660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457225PMC
April 2019
2 Reads

Chromatin remodeling factor lymphoid-specific helicase links with Epstein-Barr virus associated the follicular germinal center B cell lymphomas.

J Cancer Res Ther 2019 ;15(2):350-357

Department of Pathology, School of Basic Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Background: We assessed the frequency of epigenetic lesions, including lymphoid-specific helicase (LSH), 5-hydroxymethylcytosine (5-hmC) and E2F1, and the possible correlations among molecular findings, phenotype, clinical features, and outcome.

Methods: We investigated 181 paraffin-embedded B-cell lymphoma samples using immunohistochemistry and in situ hybridization.

Results: The levels of Ki67, LSH, 5-hmC, and E2F1 were all increased in germinal center B-cell lymphomas when compared with those in normal lymph nodes, and LSH was highly expressed in diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphomas (BLs) that were positive for Epstein-Barr virus (EBV) infection, indicating that LSH is linked to EBV infection in DLBCL and BL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.JCRT_243_18DOI Listing
January 2019
4 Reads

Chronic CD30-signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells.

Blood 2019 Apr 8. Epub 2019 Apr 8.

Research Unit Gene Vectors, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Germany

CD30 is expressed on a variety of B-cell lymphomas such as Hodgkin's lymphoma, primary effusion lymphoma, and a subgroup of diffuse large B-cell lymphoma. In normal tissues, CD30 is expressed on some activated B and T lymphocytes. However, the physiological function of CD30-signaling and its contribution to the generation of CD30-positive lymphomas are still poorly understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2018880138DOI Listing
April 2019
6 Reads

Orexin secretion abnormality involved in excessive somnolence in CNS lymphoma without hypothalamic lesions.

J Clin Neurosci 2019 Apr 5. Epub 2019 Apr 5.

Department of Gastroenterology and Neurology, Kagawa University Faculty of Medicine, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.

A 72-year-old woman developed excessive somnolence as one of the symptoms of diffuse large B-cell lymphoma in the central nervous system (CNS). Although somnolence might be caused by reduced orexin secretion associated with hypothalamic lesions, neither brain MRI nor 18F-fluorodeoxyglucose positron emission tomography identified hypothalamic lesions. However, the decreased cerebrospinal fluid (CSF) orexin levels recovered to near normal values with improvement of somnolence after chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2019.03.066DOI Listing
April 2019
1 Read

Non-squamous cell carcinoma diseases of the larynx: clinical and imaging findings.

Braz J Otorhinolaryngol 2019 Mar 16. Epub 2019 Mar 16.

Erciyes University Medical Faculty, Department of Radiology, Kayseri, Turkey.

Introduction: Squamous cell carcinoma is the most common laryngeal neoplasm and accounts for approximately 95% of all malignant neoplams of the larynx. However, various benign and malignant tumors and inflammatory diseases may affect the larynx.

Objective: The purpose of this study is to analyze the clinical and imaging findings of non-squamous cell neoplasms and inflammatory diseases of the larynx. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18088694183022
Publisher Site
http://dx.doi.org/10.1016/j.bjorl.2019.02.003DOI Listing
March 2019
5 Reads

Epstein-Barr virus-positive pyothorax-associated lymphoma expresses CCL17 and CCL22 chemokines that attract CCR4-expressing regulatory T cells.

Cancer Lett 2019 Apr 3;453:184-192. Epub 2019 Apr 3.

Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Kochi, 783-8505, Japan. Electronic address:

Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphomas associated with chronic inflammation (DLBCL-CI) develop in patients with chronic inflammation but without any predisposing immunodeficiency. Given the expression of the EBV latent genes, DLBCL-CI should have mechanisms for evasion of host antitumor immunity. EBV-positive pyothorax-associated lymphoma (PAL) is a prototype of DLBCL-CI and may provide a valuable model for the study of immune evasion by DLBCL-CI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.03.053DOI Listing
April 2019
4 Reads

Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.

BMC Cancer 2019 Apr 5;19(1):322. Epub 2019 Apr 5.

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, D-10117, Berlin, Germany.

Background: MYC is a heterogeneously expressed transcription factor that plays a multifunctional role in many biological processes such as cell proliferation and differentiation. It is also associated with many types of cancer including the malignant lymphomas. There are two types of aggressive B-cell lymphoma, namely Burkitt lymphoma (BL) and a subgroup of diffuse large cell lymphoma (DLBCL), which both carry MYC translocations and overexpress MYC but both differ significantly in their clinical outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5537-0DOI Listing
April 2019
2 Reads

Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.

Oncologist 2019 Apr 5. Epub 2019 Apr 5.

Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China

Purpose: This study aimed to develop a prognostic nomogram in diffuse large B-cell lymphoma (DLBCL) and compare it with traditional prognostic systems.

Materials And Methods: We included 1,070 consecutive and nonselected patients with DLBCL in the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, between 2006 and 2012. A nomogram based on the Cox proportional hazards model was developed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0361DOI Listing
April 2019
7 Reads

Primary Mediastinal Large B-Cell Lymphoma in a Child Presenting With Superior Mediastinal Syndrome and Chylous Pleural and Pericardial Effusion.

J Pediatr Hematol Oncol 2019 Apr 3. Epub 2019 Apr 3.

Departments of Pediatric Oncology.

Primary mediastinal (thymic) large B-cell lymphoma is an aggressive B-cell lymphoma. It comprises <3% of all pediatric non-Hodgkin lymphomas (NHLs). Primary mediastinal (thymic) large B-cell lymphoma usually presents with serous pleural effusion, but presentation with chylous pleural and pericardial effusions is rare. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001472DOI Listing
April 2019
3 Reads

Turning to Computer-Aided Drug Design in the treatment of Diffuse Large B-cell Lymphoma: Has it been helpful?

Anticancer Agents Med Chem 2019 Apr 5. Epub 2019 Apr 5.

Molecular Bio-computation and Drug Design Laboratory, School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban 4001. South Africa.

Introduction: Amidst the numerous effective therapeutic options available for the treatment of Diffuse large B-cell lymphoma (DLBCL), about 30-40% of patients treated with first-line chemoimmunotherapy still experience relapse or refractory DLBCL. This has necessitated a continuous search for new therapeutic agents to augment the existing therapeutic arsenal. The dawn of computer-aided drug design (CADD) in the drug discovery process has accounted for a persistency in the application of computational approaches either alone or in combinatorial strategies with experimental methods towards the identification of potential hit compounds with high therapeutic efficacy in abrogating DLBCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871520619666190405111526DOI Listing
April 2019
8 Reads

Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients.

Ann Hematol 2019 Apr 4. Epub 2019 Apr 4.

Department of Hematology, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Portugal.

The identification of high-risk patients deserving alternative first-line treatments to R-CHOP is a research priority in diffuse large B cell lymphoma (DLBCL). Despite the increasing recognition of biological features underlying aggressive behavior, clinical scores remain the basis for prognostic evaluation and treatment stratification in DLBCL. We performed a retrospective analysis of patients with DLBCL uniformly treated with immunochemotherapy with the aim of assessing the discriminative power of the NCCN international prognostic index (IPI) and the GELTAMO-IPI scores in risk group stratification and compared them with the IPI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03676-0DOI Listing
April 2019
1 Read

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.

Lancet Oncol 2019 Apr 1. Epub 2019 Apr 1.

Cancer Research UK Centre, University of Southampton, Southampton, UK. Electronic address:

Background: Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified using gene-expression analysis to determine their cell of origin, corresponding to germinal centre or activated B cell. We aimed to investigate whether adding bortezomib to standard therapy could improve outcomes in patients with these subtypes.

Methods: In a randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with bortezomib (REMoDL-B), an open-label, adaptive, randomised controlled, phase 3 superiority trial, participants were recruited from 107 cancer centres in the UK (n=94) and Switzerland (n=13). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30935-5DOI Listing
April 2019
7 Reads

Improving R-CHOP in diffuse large B-cell lymphoma is still a challenge.

Authors:
Fabrice Jardin

Lancet Oncol 2019 Apr 1. Epub 2019 Apr 1.

Department of Clinical Hematology, Centre Henri Becquerel, INSERM U1245, Rouen University, Rouen 76038, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30021-XDOI Listing
April 2019
5 Reads

Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma.

Leuk Lymphoma 2019 Apr 5:1-8. Epub 2019 Apr 5.

a Division of Hematology, Department of Medicine , Jichi Medical University , Tochigi , Japan.

This study sought to investigate the impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase (r/r sIL-2R) on the clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL). We determined the optimal cutoff value of r/r sIL-2R for disease progression within 6 months from salvage chemotherapy to be 861 U/mL. The high r/r sIL-2R group exhibited a significantly lower survival rate than the low r/r sIL-2R group (1-year event-free survival [EFS], 22. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1564824DOI Listing
April 2019
2 Reads

De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma.

Authors:
John P Leonard

J Clin Oncol 2019 Apr 2:JCO1900445. Epub 2019 Apr 2.

1 Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.19.00445
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00445DOI Listing
April 2019
6 Reads

Clinical characteristics and prognosis associated with multiple primary malignant tumors in non-Hodgkin lymphoma patients.

Tumori 2019 Apr 4:300891619839475. Epub 2019 Apr 4.

1 Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

Objective:: Patients with non-Hodgkin lymphoma (NHL) occasionally present with multiple primary malignant tumors (MPMTs). This study aimed to determine the clinical characteristics, survival, and risk factors of these patients.

Methods:: The median follow-up of 92 patients was 13. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0300891619839475
Publisher Site
http://dx.doi.org/10.1177/0300891619839475DOI Listing
April 2019
4 Reads

Surgical Management of Primary Bone Lymphoma of the Hip: A Case Report and Review of the Literature.

Case Rep Orthop 2019 3;2019:3174768. Epub 2019 Mar 3.

Department of Haematology, Altnagelvin Area Hospital, Glenshane Road, Londonderry, Co. Londonderry, Ireland.

Introduction: Primary bone lymphoma (PBL) is a rare bone malignancy which may present with atraumatic pain, swelling, or pathological fracture. Whilst the femur is the most commonly affected site, any bone may be involved. PBL should be distinguished from other bone lesions to determine clinical management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/3174768DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421802PMC
March 2019
3 Reads

Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.

J Cutan Med Surg 2019 Apr 3:1203475419840629. Epub 2019 Apr 3.

1 Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada.

Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin lymphomas characterized by an infiltration of malignant monoclonal T lymphocytes into the skin. Mycosis fungoides (MF), the most common subtype, and the rarer Sézary syndrome (SS), are considered the classical forms of CTCL, which, because of a varying presentation and lack of genetic and immunophenotypical markers, can often have a delayed diagnosis. With skin-directed topical treatment being the mainstay of therapy in the early stages, there is an absence of long-term curative therapies for advanced disease. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1203475419840629
Publisher Site
http://dx.doi.org/10.1177/1203475419840629DOI Listing
April 2019
7 Reads

Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively.

J Cancer Res Clin Oncol 2019 Apr 2. Epub 2019 Apr 2.

Instituto de Medicina Traslacional e Ingeniería Biomédica (IMTIB), CONICET-Instituto Universitario del Hospital Italiano-Hospital Italiano de Buenos Aires, Potosí 4240 C.P., C1183AEG, Buenos Aires, Argentina.

Purpose: Despite considerable evidence that supports the NF-kB role in the immune system and lymphomagenesis, it is unclear whether specific NF-kB dimers control a particular set of genes that account for their biological functions. Our previous work showed that Hodgkin Lymphoma (HL) is unique, among germinal center (GC)-derived lymphomas, with respect to its dependency on Rel-B to survive. In contrast, diffuse large B-Cell lymphoma (DLBCL) including both Activated B-Cell-Like and Germinal Center B-Cell-Like, requires cREL and Rel-A to survive and it is not affected by Rel-B depletion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-019-02909-zDOI Listing
April 2019
2 Reads

The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma.

Curr Oncol Rep 2019 Apr 2;21(5):44. Epub 2019 Apr 2.

Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Ave - CA6, Cleveland, OH, 44195, USA.

Purpose Of Review: Diffuse large B cell lymphoma (DLBCL) is characterized by clinical heterogeneity that is not fully accounted for by pathologic features. Furthermore, real-time treatment modifications and detection of relapse are typically guided by radiographic imaging modalities which are imperfect. Here, we review the potential utility of minimal residual disease (MRD) assessment for informing treatment decisions and detecting relapse. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0792-4
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0792-4DOI Listing
April 2019
5 Reads

Prognostic value of metabolic tumour volume on baseline F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.

Eur J Nucl Med Mol Imaging 2019 Apr 2. Epub 2019 Apr 2.

Department of Nuclear Medicine, Seoul National University, College of Medicine, Daehangro 101, Jongno-gu, Seoul, 03080, South Korea.

Purpose: The purpose of this study was to determine the prognostic value of metabolic volumetric parameters as a quantitative index on pre-treatment F-FDG PET/CT in addition to the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) in patients with diffuse large B-cell lymphoma (DLBCL).

Methods: A total of 103 consecutive patients with DLBCL and baseline FDG PET/CT were retrospectively evaluated. Quantitative metabolic parameters, including total metabolic tumour volume (TMTV) using a standardized uptake value (SUV) of ≥2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04309-4DOI Listing
April 2019
1 Read
5.383 Impact Factor

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.

Oncologist 2019 Apr 2. Epub 2019 Apr 2.

Institute of Hematology, University of Bologna, Bologna, Italy

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma subtype, and approximately 50% of the patients are >60 years of age. Patients with relapsed/refractory (rr) disease have a poor prognosis with currently available treatments. Lenalidomide is available in Italy for patients with rrDLBCL based on a local disposition of the Italian Drug Agency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0603DOI Listing
April 2019
7 Reads

Germline deletion of in familial acute lymphoblastic leukemia.

Blood Adv 2019 Apr;3(7):1039-1046

Department of Pathology, St. Jude Children's Research Hospital, Memphis TN.

Recent studies have identified germline mutations in , , , and in kindreds with familial acute lymphoblastic leukemia (ALL), but the genetic basis of ALL in many kindreds is unknown despite mutational analysis of the exome. Here, we report a germline deletion of identified by linkage and structural variant analysis of whole-genome sequencing data segregating in a kindred with thrombocytopenia, B-progenitor acute lymphoblastic leukemia, and diffuse large B-cell lymphoma. The 75-nt deletion removed the exon 7 splice acceptor, resulting in exon skipping and protein truncation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018030635DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457220PMC
April 2019
4 Reads

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

J Clin Oncol 2019 Apr 2:JCO1801994. Epub 2019 Apr 2.

14 Cornell University Medical College, New York, NY.

Purpose: Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as frontline therapy for diffuse large B-cell lymphoma.

Patients And Methods: Patients received six cycles of DA-EPOCH-R or R-CHOP. The primary objective was progression-free survival (PFS); secondary clinical objectives included response rate, overall survival (OS), and safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01994DOI Listing
April 2019
2 Reads

Front-line treatment of Diffuse large B-cell lymphoma: beyond R-CHOP.

Hematol Oncol 2019 Apr 2. Epub 2019 Apr 2.

Department of Hematology & CBMT, Ospedale di Bolzano, Bolzano, Italy.

Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with the standard immunochemotherapy R-CHOP, one-third of them relapses with a dismal outcome in most cases. In the recent years remarkable advances have been achieved based on the discovery of molecular genetics in DLBCL. In addition to the major cell-of-origin designations of germinal center B-cell and activated B-cell subtypes, next-generation sequencing has unveiled the remarkable complexity of DLBCL and identified potential molecular targets for tailored therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2613DOI Listing
April 2019
3 Reads